Udvalget fandt derfor, at fordelene ved Fareston opvejer risiciene til førstevalgsbehandling af hormonafhængig metastatisk brystkræft hos kvinder efter overgangsalderen.
Therefore, the Committee decided that Fareston’ s benefits are greater than its risks for the first line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.